FY2028 Earnings Forecast for AbbVie Issued By William Blair

AbbVie Inc. (NYSE:ABBV - Free Report) - Equities research analysts at William Blair issued their FY2028 earnings per share estimates for shares of AbbVie in a note issued to investors on Monday, June 30th. William Blair analyst M. Phipps expects that the company will post earnings of $16.15 per share for the year. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. The business had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The business's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.31 earnings per share.

ABBV has been the topic of a number of other research reports. Wall Street Zen lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald initiated coverage on AbbVie in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $210.00 target price on the stock. Guggenheim lifted their price target on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Morgan Stanley boosted their price target on AbbVie from $241.00 to $250.00 and gave the company an "overweight" rating in a research note on Monday, April 28th. Finally, Bank of America raised their price objective on AbbVie to $204.00 and gave the stock a "hold" rating in a research note on Monday, June 9th. Eight equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, AbbVie currently has an average rating of "Moderate Buy" and an average target price of $211.29.

AbbVie Stock Performance

Shares of AbbVie stock traded down $1.25 during midday trading on Thursday, hitting $189.50. The company had a trading volume of 3,706,217 shares, compared to its average volume of 6,248,905. The company has a fifty day simple moving average of $187.30 and a 200 day simple moving average of $188.36. The stock has a market cap of $334.73 billion, a price-to-earnings ratio of 80.64, a PEG ratio of 1.27 and a beta of 0.48. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. AbbVie has a 12-month low of $163.63 and a 12-month high of $218.66.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a $1.64 dividend. The ex-dividend date is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.46%. AbbVie's dividend payout ratio is currently 279.15%.

Hedge Funds Weigh In On AbbVie

A number of large investors have recently added to or reduced their stakes in the stock. LaFleur & Godfrey LLC lifted its position in shares of AbbVie by 4.1% in the fourth quarter. LaFleur & Godfrey LLC now owns 79,396 shares of the company's stock valued at $14,109,000 after acquiring an additional 3,108 shares in the last quarter. Brighton Jones LLC raised its stake in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in AbbVie by 11.1% in the 4th quarter. Fisher Asset Management LLC now owns 43,233 shares of the company's stock valued at $7,683,000 after purchasing an additional 4,319 shares in the last quarter. Finally, Synergy Investment Management LLC acquired a new stake in AbbVie during the 4th quarter worth $48,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.